Investigational drug · Phase 3
ABP 206
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
95
Any phase or sponsor naming "ABP 206"
First trial start
2023
Jul 26, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABP 206", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma
Largest trials
Live from ClinicalTrials.gov: studies naming "ABP 206" as an intervention, largest first.
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05675410 · 1,875 participants (planned) · Start May 11, 2023 · Primary completion Apr 28, 2031
Drug: Bleomycin Sulfate; Brentuximab Vedotin and 11 more · For: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 419 sites in all
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03793166 · 1,175 participants (planned) · Start Jun 7, 2019 · Primary completion Mar 1, 2028
Drug: Cabozantinib; Ipilimumab and 1 more · For: Clear Cell Renal Cell Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Lymph Nodes and 6 more
Sites: Mobile, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 859 sites in all
- Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03907488 · 994 participants · Start Aug 29, 2019 · Primary completion Mar 31, 2024
Drug: Brentuximab Vedotin; Dacarbazine and 5 more · For: Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma and 7 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 728 sites in all
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05987241 · 992 participants (planned) · Start Feb 2, 2024 · Primary completion Sep 2, 2030
Drug: Nivolumab; Relatlimab · For: Muscle Invasive Bladder Urothelial Carcinoma; Muscle Invasive Renal Pelvis Urothelial Carcinoma; Muscle Invasive Ureter Urothelial Carcinoma and 4 more
Sites: Phoenix, Arizona; Tucson, Arizona; Fayetteville, Arkansas · 505 sites in all
- Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)Pivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02595944 · 903 participants (planned) · Start Jul 22, 2016 · Primary completion May 31, 2027
Drug: Nivolumab · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 884 sites in all
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing NephrectomyPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03055013 · 819 participants · Start Apr 28, 2017 · Primary completion May 24, 2023
Drug: Nivolumab · For: Metastatic Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage II Renal Cell Cancer AJCC v7 and 2 more
Sites: Birmingham, Alabama; Gilbert, Arizona; Phoenix, Arizona · 413 sites in all
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02834013 · 798 participants · Start Jan 30, 2017 · Primary completion May 1, 2026
Drug: Ipilimumab; Nivolumab · For: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma and 91 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 1,007 sites in all
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT07383441 · 718 participants (planned) · Start Jun 5, 2026 · Primary completion Jan 31, 2033
Drug: Axitinib; Cabozantinib and 7 more · For: Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8 and 1 more
Sites: Fayetteville, Arkansas; Jonesboro, Arkansas; Rogers, Arkansas · 41 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.